Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK’s Post-Advair Day Has Dawned, But Breo And Anoro Not Yet Shining

This article was originally published in The Pink Sheet Daily

Executive Summary

Decline in Advair sales to cointinue for several years as the portfolio transitions to new products, which have faced reimbursement challenges.

You may also be interested in...



China Scandal One Early Challenge For New GSK Chairman

Philip Hampton likely will have to deal with the fallout from the Chinese bribery scandal, as well as a major restructuring of the previously announced asset swap with Novartis, and increasing generic competition to its leading products.

Emerging Markets Earnings Roundup: GlaxoSmithKline (Part 4)

GlaxoSmithKline CEO Andrew Witty took a question on the China compliance investigation and quickly moved on in an earnings call also thin on emerging market plans. However, the earnings release added a bit of detail on both fronts, including up-to-date details on regulatory aspects outside of China.

Emerging Markets Earnings Roundup: GlaxoSmithKline (Part 4)

GlaxoSmithKline CEO Andrew Witty took a question on the China compliance investigation and quickly moved on in an earnings call also thin on emerging market plans. However, the earnings release added a bit of detail on both fronts, including up-to-date details on regulatory aspects outside of China.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel